BECOME A MEMBER
There are various types of membership available.
American Society of Hematology (ASH) 2011 - Chronic Lymphocytic Leukaemia
Source: EJCMO.tv
Patients with refractory chronic lymphocytic leukaemia (CLL) have an unfavourable prognosis and continue to pose a daunting challenge for the haematologist. In particular, we are now seeing refractoriness not just with fludarabine but also fludarabine-combinations (e.g. cyclophosphomide, rituximab and alemtuzumab). But there are emerging treatment options for these patients beyond enrolling them in clinical trials. Drs Peter Hillman, Stephan Stilgenbauer, William Wierda and Susan O'Brien discuss and debate emerging evidence in treating patients with refractory CLL in a four-part video series.
Emerging evidence in treating CLL patients
Clinical evidence - ofatumumab
Managing adverse effects - ofatumumab
Preventing infusion-related adverse reactions
